DKSH Technology acquires Korean life science firm MDxK

The acquisition of MDxK further strengthens the Business Unit’s position in the molecular diagnostics market

Merck seeks FDA approval for subcutaneous pembrolizumab

Subcutaneous pembrolizumab administered every six weeks with a median injection time of two minutes, in combination with chemotherapy, shows consistent results across reported efficacy and safety endpoints compared to IV KEYTRUDA in combination with chemotherapy

Bio-Thera & Dr Reddy’s execute commercialization pact for biosimilars Stelara & Simponi for SE Asia

Bio-Thera will maintain responsibility for development, manufacturing, and supply of BAT2206 and BAT2506

European Commission approves Merck’s Capvaxive for prevention of invasive pneumococcal disease

EC decision marks the fourth approval for CAPVAXIVE for pneumococcal vaccination in adults

Cadila launches Cadilose for constipation and hepatic encephalopathy

Alembic Pharma and Amlan International partner to advance poultry health in India

Alembic Pharmaceuticals Ltd. and Amlan International sign exclusive strategic commercial agreement to make poultry health innovations accessible to Indian farmers and integrators

Merck inks $200 million deal for Hengrui's midstage heart disease drug

Hengrui Pharma has granted Merck exclusive rights to develop, manufacture and commercialize HRS-5346 worldwide, excluding Greater China region

Wipro announces AI Agent Solutions across healthcare industry

Wipro’s agents for Agentforce will elevate efficiency and customer satisfaction at healthcare companies

Our TB elimination strategy is based on ‘whole of the society’ and ‘whole of the government’ approach: JP Nadda

Nadda noted that TB treatment coverage in India has increased from 59% to 85%

Briefs: Alembic Pharmaceuticals and Shelter Pharma

Alembic Pharmaceuticals successfully completes USFDA inspection for API-III facility